ストックスクリーナーアプリを入手
32.10
6.30%
-2.16
アフターアワーズ：
32.02
-0.08
-0.25%
Definium Therapeutics Inc (DFTX) 最新ニュース
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Definium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC Filing - Yahoo Finance
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock - Investing.com
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares - Investing.com
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares By Investing.com - Investing.com Nigeria
Definium Therapeutics CCO Matthew Wiley sells $113,257 in common shares By Investing.com - Investing.com Nigeria
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares By Investing.com - Investing.com UK
Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock By Investing.com - Investing.com UK
Definium Therapeutics CCO Matthew Wiley sells $113,257 in common shares - Investing.com
Definium Therapeutics CLO Mark Sullivan sells $513,845 in shares - Investing.com
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares - Investing.com
To cover taxes, Definium Therapeutics (DFTX) medical chief sells 10,853 shares. - Stock Titan
To cover taxes on vested stock grants, Definium Therapeutics (DFTX) CEO sold 31,550 shares. - Stock Titan
To cover vesting taxes, Definium Therapeutics (DFTX) officer sells 3,097 shares. - Stock Titan
To cover stock-grant taxes, Definium Therapeutics (DFTX) legal chief sells 14,051 shares. - Stock Titan
To cover vesting taxes, Definium Therapeutics (DFTX) CFO sells 3,377 shares. - Stock Titan
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
An officer sold 2,867 shares in the prior three months and lists 3,097 for sale at Definium Therapeutics (DFTX). - Stock Titan
After selling 3,013 shares in June, a Definium Therapeutics (DFTX) officer proposes selling 3,377. - Stock Titan
After selling 13,008 shares in June, Definium Therapeutics (DFTX) officer Mark Sullivan proposes to sell 14,051. - Stock Titan
After selling 10,035 shares in June, a Definium Therapeutics (DFTX) officer proposes another sale. - Stock Titan
Director at Definium Therapeutics (DFTX) now holds 22,296 shares - Stock Titan
Director boosts Definium (DFTX) stake with option exercise - Stock Titan
Definium Therapeutics (NasdaqGS:DFTX) Stock Forecast & Analyst Predictions - Simply Wall Street
Definium (DFTX) CEO awarded 750,000 shares tied to clinical milestones - Stock Titan
Definium Therapeutics (DFTX) grants CFO 125,000 stock units tied to milestones - Stock Titan
Definium (DFTX) legal chief now holds 508K shares - Stock Titan
Definium Therapeutics (DFTX) awards 125K performance shares tied to 2028 milestones - Stock Titan
Equity grant lifts Definium Therapeutics (DFTX) CMO stake to 803,699 shares - Stock Titan
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Definium Therapeutics' Upcoming Phase 3 Data on DT120 to De-Risk Program, Back FDA Approval, RBC Says - marketscreener.com
DFTX Reiterated by RBC Capital -- Price Target Maintained at $66.00 - GuruFocus
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - BioSpace
Definium Therapeutics (DFTX) Showcases Phase 3 Data Amid High Va - GuruFocus
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - Yahoo Finance
DFTXDefinium Therapeutics Inc Revenue Breakdown - Finviz
Definium Therapeutics CEO Robert Barrow Sells 19,023 Shares Following 40,000-Share Award - Kalkine Media
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com Nigeria
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com UK
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
5.43%
大文字化:
|
ボリューム (24 時間):